Clarence L. Fortner
- Clinical Biochemistry top 2%
- Bacterial Identification and Susceptibility Testing 5
- Molecular Medicine top 5%
- Oncology top 10%
- Neutropenia and Cancer Infections 11
- Pharmacology top 5%
- Antibiotics Pharmacokinetics and Efficacy 6
-
- Antimicrobial Resistance in Staphylococcus 4
-
- Acute Lymphoblastic Leukemia research 4
-
- Pharmaceutical studies and practices 3
- Childhood Cancer Survivors' Quality of Life 2
-
- Testicular diseases and treatments 2
- Co-authors
- Stephen C. SchimpffPeter H. WiernikViola Mae YoungJames C. WadeHarold C. StandifordDavis M. HahnRebecca S. FinleyWilliam R. Grove
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (2 papers)Cancer (1 paper)
- Partner nations
- United StatesMalaysia
In The Last Decade
Clarence L. Fortner
28 papers receiving 663 citations
Peers
Comparison fields: 5 of 102
- Clinical Biochemistry 215
- Molecular Medicine 153
- Oncology 431
- Pharmacology 246
- Applied Microbiology and Biotechnology 20
Countries citing papers authored by Clarence L. Fortner
This map shows the geographic impact of Clarence L. Fortner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clarence L. Fortner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clarence L. Fortner more than expected).
Fields of papers citing papers by Clarence L. Fortner
This network shows the impact of papers produced by Clarence L. Fortner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clarence L. Fortner. The network helps show where Clarence L. Fortner may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Clarence L. Fortner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1992 | 5 | |
| 2 | 1986 | 35 | |
| 3 | 1985 | 2 | |
| 4 | 1985 | 10 | |
| 5 | 1985 | 32 | |
| 6 | 1982 | 13 | |
| 7 | 1981 | 128 | |
| 8 | 1981 | 75 | |
| 9 | 1980 | 39 | |
| 10 | 1979 | 77 | |
| 11 | 1978 | 23 | |
| 12 | 1978 | 53 | |
| 13 | 1978 | 1 | |
| 14 | 1977 | 25 | |
| 15 | 1976 | 33 | |
| 16 | 1976 | 14 | |
| 17 | Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. | 1976 | 39 |
| 18 | 1975 | 22 | |
| 19 | 1971 | 0 | |
| 20 | 1969 | 16 |
About Clarence L. Fortner
Clarence L. Fortner is a scholar working on Clinical Biochemistry, Geriatrics and Gerontology and Pharmacology, having authored 30 papers that have together received 841 indexed citations. Recurring topics across this work include Neutropenia and Cancer Infections (11 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers), Bacterial Identification and Susceptibility Testing (5 papers), Antimicrobial Resistance in Staphylococcus (4 papers), Acute Lymphoblastic Leukemia research (4 papers), Pharmaceutical studies and practices (3 papers), Testicular diseases and treatments (2 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). The work is most often cited by research in Clinical Biochemistry (215 citations), Molecular Medicine (153 citations) and Oncology (431 citations). Clarence L. Fortner has collaborated with scholars based in United States and Malaysia. Frequent co-authors include Stephen C. Schimpff, Peter H. Wiernik, Viola Mae Young, James C. Wade, Harold C. Standiford, Davis M. Hahn, Rebecca S. Finley, William R. Grove, Kathryn A. Newman and John F. Bender. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.